Aspirin For MI Primary Prevention Indication Needs More Study, Panel Says
This article was originally published in The Tan Sheet
Executive Summary
A long-term randomized prospective trial of at least 15,000 patients would be needed to adequately support professional aspirin labeling on primary prevention of myocardial infarction, according to members of FDA's Cardiovascular & Renal Drugs Advisory committee
You may also be interested in...
WHS Findings Back Expanded Aspirin Professional Labeling – Bayer
Results from the Women's Health Study showing the effects of aspirin therapy in women support Bayer Consumer Care's citizen petition requesting expanded professional labeling, the firm says
WHS Findings Back Expanded Aspirin Professional Labeling – Bayer
Results from the Women's Health Study showing the effects of aspirin therapy in women support Bayer Consumer Care's citizen petition requesting expanded professional labeling, the firm says
WHS Findings Back Expanded Aspirin Professional Labeling – Bayer
Results from the Women's Health Study showing the effects of aspirin therapy in women support Bayer Consumer Care's citizen petition requesting expanded professional labeling, the firm says